title: Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs.
abstract: The objective of this study was to develop doxofylline-loaded sustained-release pellets coated with Eudragit NE30D alone (F1) or blend of Eudragit RL30D/RS30D (F2) and further evaluate their in vitro release and in vivo absorption in beagle dogs. Doxofylline-loaded cores with a drug loading of 70% (w/w) were prepared by layering drug-MCC powder onto seed cores in a centrifugal granulator and then coating them with different kinds of polymethacrylates in a bottom-spray fluidized bed coater. Dissolution behaviour of these formulations was studied in vitro under various pH conditions (from pH 1.2 to pH 7.4) to evaluate the effect of pH on drug release profiles. It was found that F2 produced a better release profile than F1 did and two different release mechanisms were assumed for F1 and F2, respectively. The relative bioavailability of the sustained-release pellets was studied in six beagle dogs after oral administration in a fast state using a commercially available immediate release tablet as a reference. Coated with Eudragit NE30D and a blend of Eudragit RL30D/RS30D (1:12), at 5% and 8% coating level, respectively, the pellets acquired perfect sustained-release properties and good relative bioavailability, with small fluctuation of drug concentration in plasma. But combined use of mixed Eudragit RL30D/RS30D polymers with proper features as coating materials produced a longer T(max), a lower C(max) and a little higher bioavailability compared to F1 (coated with Eudragit NE30D alone). The C(max), T(max) and relative bioavailability of F1 and F2 coated pellets were 15.16 microg/ml, 4.17 h, 97.69% and 11.41 microg/ml, 5 h, 101.59%, respectively. Also a good linear correlation between in vivo absorption and in vitro release was established for F1 and F2, so from the dissolution test, formulations in vivo absorption can be properly predicted.
authors.affiliation: College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People's Republic of China.
authors.forename: Hui-Feng
authors.initials: HF
authors.lastname: Huang
authors.forename: Yan
authors.initials: Y
authors.lastname: Lu
authors.forename: Hai-Bing
authors.initials: HB
authors.lastname: He
authors.forename: Xing
authors.initials: X
authors.lastname: Tang
mesh_terms: D000180:Acrylic Resins / Q000737:chemistry; D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D001993:Bronchodilator Agents / Q000493:pharmacokinetics*; D002482:Cellulose / Q000737:chemistry; D003692:Delayed-Action Preparations; D004285:Dogs; D006863:Hydrogen-Ion Concentration; D008297:Male; D008689:Methacrylates / Q000737:chemistry*; D011108:Polymers / Q000737:chemistry*; D012995:Solubility; D013806:Theophylline / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
chemical_list: D000180:Acrylic Resins; D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; C477853:Eudragit NE 30-D; D008689:Methacrylates; D011108:Polymers; C050528:Eudragit RS; C058665:Eudragit RL; D002482:Cellulose; D013806:Theophylline; C029797:doxofylline; C109691:microcrystalline cellulose